APOC3 and atherosclerosis: To determine if apoC-III–knockdown strategies can improve atherosclerosis, we administered an ASO against Apoc3 (50 mg/kg/w) to mouse models that differ in their metabolic response to apoC-III inhibition (Figure 1, A–C).